Odds ratio vs risk ratio in randomized controlled trials

Postgraduate Medicine
Haribalakrishna BalasubramanianSanjay Patole

Abstract

Use of odds ratio (OR) in randomized controlled trials (RCTs) has been criticized because it overestimates the effect size, if incorrectly interpreted as risk ratio (RR). To what extent does this make a difference in the context of clinical research is unclear. We, therefore, aimed to address this issue considering its importance in evidence-based practice of medicine. We reviewed 580 RCTs published in the New England Journal of Medicine between January 2004 and June 2014 and identified 107 RCTs that reported unadjusted RR (n = 76) or OR (n = 31) for the primary outcome. For studies reporting ORs, we calculated RRs, and vice versa, using Stata software. The percentage of divergence between the reported and calculated effect size estimates was analyzed. None of the RCTs showed a statistically significant result becoming insignificant or vice versa depending on the effect size estimate. OR exaggerated the RR in 62% of the RCTs. The percentage of overestimation was > 50% in 28 RCTs and > 100% in 13 RCTs. The degree of overestimation was positively correlated with the prevalence of outcomes (spearman's rho = 0.84 and 0.66, p < 0.001). Use of OR instead of RR in RCTs does not change the qualitative inference of results. However, the...Continue Reading

References

Dec 1, 1991·Statistics in Medicine·D G Altman
Apr 29, 1998·BMJ : British Medical Journal·H T DaviesM Tavakoli
Sep 29, 2001·Obstetrics and Gynecology·W L HolcombK D Burgdorf
Nov 10, 2001·Journal of Andrology·S D Simon
Sep 26, 2002·Epidemiology·K J Rothman
May 15, 2003·American Journal of Epidemiology·Louise-Anne McNuttJean Paul Hafner
Sep 17, 2003·Anaesthesia and Intensive Care·K M HoS Walters
Dec 26, 2003·Radiology·Christopher L Sistrom, Cynthia W Garvan
Jan 9, 2004·The New England Journal of Medicine·Raffaele LandolfiUNKNOWN European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
Jan 16, 2004·The New England Journal of Medicine·Adnan KastratiUNKNOWN Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators
Apr 23, 2004·The New England Journal of Medicine·Maria Beatriz M PerondiRobert A Berg
May 28, 2004·The New England Journal of Medicine·Simon FinferUNKNOWN SAFE Study Investigators
Jul 9, 2004·The New England Journal of Medicine·Marie-Victoire SenatYves Ville
Oct 16, 2004·The New England Journal of Medicine·Monique PrinssenUNKNOWN Dutch Randomized Endovascular Aneurysm Management (DREAM)Trial Group
Oct 22, 2004·The New England Journal of Medicine·Guy E ThwaitesJeremy J Farrar
Feb 18, 2005·The New England Journal of Medicine·Matthew R GoldenKing K Holmes
Mar 5, 2005·The New England Journal of Medicine·Nicholas A MaskellUNKNOWN First Multicenter Intrapleural Sepsis Trial (MIST1) Group
Mar 9, 2005·The New England Journal of Medicine·Paul M RidkerJulie E Buring
Jun 14, 2005·The New England Journal of Medicine·Caroline A CrowtherUNKNOWN Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group
Jul 8, 2005·The New England Journal of Medicine·Karen K L MestanMichael D Schreiber
Sep 2, 2005·The New England Journal of Medicine·William D FraserUNKNOWN Amnioinfusion Trial Group
Sep 9, 2005·The New England Journal of Medicine·Giampaolo BucaneveUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program
Sep 9, 2005·The New England Journal of Medicine·Michael CullenUNKNOWN Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number
Sep 16, 2005·The New England Journal of Medicine·Robbert J de WinterUNKNOWN Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators
Mar 15, 2006·The New England Journal of Medicine·Eva LonnUNKNOWN Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Mar 16, 2006·The New England Journal of Medicine·Stevo JuliusUNKNOWN Trial of Preventing Hypertension (TROPHY) Study Investigators
Mar 16, 2006·The New England Journal of Medicine·Elliott M AntmanUNKNOWN ExTRACT-TIMI 25 Investigators
Mar 17, 2006·The New England Journal of Medicine·Evangelos G PapanikolaouPaul Devroey
Apr 11, 2006·Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine·Ian Shrier, Russell Steele
Apr 21, 2006·The New England Journal of Medicine·Stephen B FreedmanElizabeth C Powell
Apr 28, 2006·The New England Journal of Medicine·Alice R RumboldUNKNOWN ACTS Study Group
May 19, 2006·The New England Journal of Medicine·Barbara SchmidtUNKNOWN Caffeine for Apnea of Prematurity Trial Group
Jul 28, 2006·The New England Journal of Medicine·John P KinsellaSteven H Abman
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
Jan 26, 2007·The New England Journal of Medicine·Andrew J UllmannSimon Durrant
May 4, 2007·The New England Journal of Medicine·Dennis M BlackUNKNOWN HORIZON Pivotal Fracture Trial
Jun 22, 2007·The New England Journal of Medicine·Joann E MansonUNKNOWN WHI and WHI-CACS Investigators
Jul 20, 2007·The New England Journal of Medicine·UNKNOWN Warfarin Antiplatelet Vascular Evaluation Trial InvestigatorsGilbert Gosselin
Aug 3, 2007·The New England Journal of Medicine·Dwight J RouseUNKNOWN National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network
Aug 3, 2007·The New England Journal of Medicine·Eduardo B FonsecaUNKNOWN Fetal Medicine Foundation Second Trimester Screening Group
Aug 10, 2007·The New England Journal of Medicine·Marilyn J Manco-JohnsonBruce L Evatt
Sep 1, 2007·The New England Journal of Medicine·UNKNOWN SAFE Study InvestigatorsShirley Vallance
Sep 7, 2007·The New England Journal of Medicine·Howard L CorwinUNKNOWN EPO Critical Care Trials Group
Nov 9, 2007·The New England Journal of Medicine·Barbara SchmidtUNKNOWN Caffeine for Apnea of Prematurity Trial Group
Dec 14, 2007·The New England Journal of Medicine·Thi Hoang Mai NguyenJeremy J Farrar
Dec 14, 2007·The New England Journal of Medicine·Matthew ScarboroughEduard E Zijlstra
Feb 2, 2008·Obstetrics and Gynecology·David A Grimes, Kenneth F Schulz

❮ Previous
Next ❯

Citations

Aug 21, 2016·British Journal of Anaesthesia·E Fominskiy, G Landoni
May 21, 2019·Interdisciplinary Sciences, Computational Life Sciences·Yonghong ZhangMingyang Dong
Mar 1, 2019·American Journal of Physical Medicine & Rehabilitation·Suneel UpadhyeDinesh Kumbhare
Jun 25, 2020·Journal of Hypertension·Nicolas BeckerChristian Ukena
Apr 6, 2018·Therapeutic Advances in Musculoskeletal Disease·Olivia L TsengMartin G Dawes
Aug 10, 2020·Journal of Hypertension·Costas Thomopoulos
Jul 19, 2019·American Journal of Physical Medicine & Rehabilitation·Suneel UpadhyeDinesh Kumbhare
Nov 11, 2020·Journal of Clinical Epidemiology·Suhail A DoiLukman Thalib

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.